Haemonetics Q3 Adjusted EPS $1.04 Beats $0.94 Estimate, Sales $336.25M Beat $320.29M Estimate
Portfolio Pulse from Benzinga Newsdesk
Haemonetics (NYSE:HAE) reported Q3 adjusted EPS of $1.04, surpassing the $0.94 estimate, and sales of $336.25M, exceeding the $320.29M estimate. This represents a 22.35% increase in earnings and a 10.14% increase in sales from the same period last year.
February 08, 2024 | 11:02 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Haemonetics reported a significant beat on both earnings and sales estimates for Q3, with a notable year-over-year growth in both metrics.
Beating earnings and sales estimates typically leads to positive investor sentiment and can cause a short-term increase in stock price. The substantial year-over-year growth in both earnings and sales further strengthens the case for a positive impact on Haemonetics' stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100